Navigation Links
Cell therapy using patient's own bone marrow may present option for heart disease
Date:3/24/2012

CHICAGO Cell therapy may present an option for patients with ischemic heart disease to use their own bone marrow cells to repair the damaged areas of their hearts, and may pave the way for future treatment options, according to the FOCUS trial, which will be presented as a late-breaking clinical trial March 24 at the 61st annual American College of Cardiology (ACC) scientific session.

This is the largest study to date to look at stem cell therapy, using a patient's own stem cells, to repair damaged areas of the heart in patients with chronic ischemic heart disease and left ventricular dysfunction. Researchers found that left ventricular ejection fraction (the percentage of blood leaving the heart's main pumping chamber) increased by a small but significant amount (2.7 percent) in patients who received stem cell therapy. The study also revealed that the improvement in ejection fraction correlated with the number of progenitor cells (CD34+ and CD133+) in the bone marrow; and this information will help in evaluating and designing future therapies and trials.

"FOCUS is an incredibly important trial, as it has informed the cell therapy community how to better treat this high-risk patient population, and allows us to enter into an exciting, next generation of stem cell therapy armed with more data," said study investigator Timothy D. Henry, MD, an interventional cardiologist at the Minneapolis Heart Institute (MHI) at Abbott Northwestern Hospital in Minneapolis and director of research with the Minneapolis Heart Institute Foundation.

This multicenter study was conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), which is supported through a research grant from the National Institutes of Health's National, Heart, Lung and Blood Institute (NHLBI), with the goal to evaluate novel stem cell-based treatment strategies for individuals with cardiovascular disease.

FOCUS will be presented at ACC.12 by its lead investiga
'/>"/>

Contact: Kristin Wincek
kwincek@mhif.org
612-863-0249
Minneapolis Heart Institute Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
2. Researchers discover novel therapy for Crohns disease
3. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
4. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
7. Molecules role in cancer suggests new combination therapy
8. Cancer therapy more potent when it hits 2 targets
9. Immunological mechanisms of oncolytic adenoviral therapy
10. Aiding cancer therapy by mathematically modeling tumor-immune interactions
11. Gene therapy is a disruptive science ready for commercial development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... have identified a handful of bacterial culprits that may ... and ulcerative colitis, using patients, own intestinal immune responses ... 28 in the journal Cell . , Trillions ... plays a critical role in the development and progression ... number of bacterial species affect a person,s susceptibility to ...
(Date:8/28/2014)... your neighbors than traditional cigarettes, but still release ... study from USC. , Scientists studying secondhand smoke ... exposure to harmful particles, with close-to-zero exposure to ... harmful metals in second-hand e-cigarette smoke were found ... contains high levels of polycyclic aromatic hydrocarbons ...
(Date:8/28/2014)... MINNEAPOLIS/ST. PAUL (August 28, 2014) Researchers at the ... for facioscapulohumeral muscular dystrophy (FSHD) to be used for ... effectiveness of potential therapies for FSHD. , The research ... Cell Reports . , There is no treatment ... the most common type of muscular dystrophy. FSHD is ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2
... of viruses to effectively combat them: That is ... received its funding commitment today. VISTRIE, which stands ... joint program grant with independent management structures receiving ... Centres. Coordinated by the German Helmholtz Centre for ...
... June 30, 2011 Jerusalem, Israel The Israeli ... industrial R&D and innovation, has released new data from ... and strategic consulting firm Applied Economics Ltd., to mark ... anniversary. The study presents the proven impact of ...
... functional properties, or traits, has been pub-lished. Scientists ... the world,s 300,000 plant species. The achievement rests ... re-search institutions. The initiative, known as TRY, is ... in Jena (Germany). Jointly coordinated with the University ...
Cached Biology News:Virtual Institute investigates virus infections 2Is governmental investment in industrial R&D paying off? 2Is governmental investment in industrial R&D paying off? 3Global plant database set to promote biodiversity research and Earth-system sciences 2
(Date:8/28/2014)... City, CA (PRWEB) August 28, 2014 ... sanitation products for the food processing industry, is asking ... a side-by side comparison of the E2 soap they’re ... E2 Sanitizing Foam Soap . Hand hygiene is ... in the food processing environment. Six key criteria are ...
(Date:8/28/2014)... an electronic which is not only based on ... spin and the spin-related magnetism. Spin-charge converters enable ... vice versa. Recently, the research group of Professor ... Johannes Gutenberg University Mainz in collaboration with researchers ... the first time realised a new, efficient spin-charge ...
(Date:8/28/2014)... --  SunTrust Robinson Humphrey (STRH) today announced ... equity research team in biotechnology and oilfield services.  ... research demonstrates our commitment to providing our valued ... investment decision making," said Biff Woodruff , ... make significant investments in differentiated content at a ...
(Date:8/28/2014)... (PRWEB) August 27, 2014 Scientists, researchers, ... for SPIE Laser Damage 2014 symposium. Marking ... for high-power lasers will run 14-17 September. The event ... optics and photonics . , The premier conference for ... laser damage to optical materials will engage researchers and ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... Guidance and Remains on Track for Four Product Launches ... 9:00 a.m. EDT EATONTOWN, N.J., April 30 Osteotech, ... the emerging field of biologic products for regenerative healing, ... 31, 2009."During the first quarter, we continued to make ...
... Accomplished regulatory executive enhances Nfocus device development team.PALO ALTO, ... Neuromedical Inc. announced today the appointment of accomplished ... the role of Vice President of Regulatory Affairs. "Bob ... experience to Nfocus , having served 18 of ...
... shows potential for pirfenidone role in treatment of patients with ... in HCV -- Strong data from 14-day triple combination study ... InterMune, Inc. (Nasdaq: ITMN ) today announced ... 2009. InterMune reported a net loss for ...
Cached Biology Technology:Osteotech Reports First Quarter 2009 Financial Results 2Osteotech Reports First Quarter 2009 Financial Results 3Osteotech Reports First Quarter 2009 Financial Results 4Osteotech Reports First Quarter 2009 Financial Results 5Osteotech Reports First Quarter 2009 Financial Results 6Osteotech Reports First Quarter 2009 Financial Results 7Osteotech Reports First Quarter 2009 Financial Results 8Nfocus Neuromedical Appoints Robert O'Holla to Head Regulatory 2InterMune Reports First Quarter 2009 Financial Results and Business Highlights 2InterMune Reports First Quarter 2009 Financial Results and Business Highlights 3InterMune Reports First Quarter 2009 Financial Results and Business Highlights 4InterMune Reports First Quarter 2009 Financial Results and Business Highlights 5InterMune Reports First Quarter 2009 Financial Results and Business Highlights 6InterMune Reports First Quarter 2009 Financial Results and Business Highlights 7InterMune Reports First Quarter 2009 Financial Results and Business Highlights 8InterMune Reports First Quarter 2009 Financial Results and Business Highlights 9InterMune Reports First Quarter 2009 Financial Results and Business Highlights 10InterMune Reports First Quarter 2009 Financial Results and Business Highlights 11InterMune Reports First Quarter 2009 Financial Results and Business Highlights 12InterMune Reports First Quarter 2009 Financial Results and Business Highlights 13
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
... The new Finnpipette Focus Long ... cone for pipetting from test ... narrow and long necked vessels. ... whatever volume you select, it ...
Biology Products: